CD4 News and Research

RSS

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Penn researchers reveal complex details of T-cell responses to mRNA COVID-19 vaccines

Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system's T cells-;the heavy armor of the immune system-;according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

16 Aug 2021

Risk factors for hospitalization among HIV patients infected with SARS-CoV-2

The hospitalization of PWH with COVID-19 is related to host factors such as older age and co-morbidities, rather than due to traditional metrics of HIV.

11 Aug 2021

COVID-19 vaccine likely protects people living with HIV, study shows

A Johns Hopkins Medicine research team has shown that people living with the human immunodeficiency virus (HIV) are likely to be protected against SARS-CoV-2, the virus that causes COVID-19, if they are fully vaccinated.

11 Aug 2021

Long COVID may be due to persistent immune disturbances

A new study discusses abnormalities in the immune response following COVID-19 in samples collected from patients who have recovered from COVID-19.

8 Aug 2021

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

In a paper recently uploaded to the preprint server bioRxiv* by Kulkarni et al. (August 3, 2021), the potential of vaccinia virus-based vaccines expressing the full-length SARS-CoV-2 spike protein is examined in mice and Syrian hamsters. The findings report that the vaccine generates high titers of neutralizing antibodies with good activity towards SARS-CoV-2 variants of concern.

5 Aug 2021

Heterologous prime-boost vaccination induces robust mucosal and systemic immunity against SARS-CoV-2

Scientists from Germany and Italy recently demonstrated the benefits of intramuscular/intranasal heterologous prime-boost vaccination regimen against coronavirus disease 2019 (COVID-19).

4 Aug 2021

Next-generation CRISPR tools and therapies improved by modified RNA guides

A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).

3 Aug 2021

Study sheds light on oral vaccine failure in mouse model of chronic gut disorder

A chronic gut disorder that occurs in regions with poor sanitation disrupts intestinal immune responses and impairs oral vaccine effectiveness in a mouse model of the disease, according to research led by UPMC Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine scientists.

3 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

Streptococcus pneumoniae modulates host immunity to SARS-CoV-2

Scientists from the UK and US have recently investigated immunological consequences of secondary Streptococcus pneumoniae (S. pneumoniae) infection in coronavirus disease 2019 (COVID-19) patients.

29 Jul 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

A team of international scientists has recently developed virus-like particles (VLPs) by coating liposomes with the synthetic spike glycoprotein of SARS-CoV-2.

28 Jul 2021

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

A study analyzes the immune responses of medical personnel, as well as immunocompromised DP and immunosuppressed KTR patients.

27 Jul 2021

T cells are not critical for recovery of primates from acute COVID-19 infections, study reveals

New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections.

27 Jul 2021

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

A new study evaluates a commercially available IFN‐γ release assay (IGRA) to determine T-cell responses targeted against SARS-CoV-2.

26 Jul 2021

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

A new study discusses how both different responses to the infection itself and to COVID-19 vaccines are likely the result of genetic differences.

25 Jul 2021

Research uncovers an unexpected role for immune T cells in protection against malaria

Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.

23 Jul 2021

Exhausted T cells linked to increased risk of COVID-19 mortality

New research led by Nadia R. Roan of Gladstone Institutes and the University of California, San Francisco, finds a correlation between high numbers of inflammatory CXCR4+ T cells and regulatory T cells specific to SARS-CoV-2 and dying from infection. In contrast, people who recovered from severe COVID-19 illness were more likely to have many SARS-CoV-2-specific T cells that perform homeostatic proliferation.

20 Jul 2021